The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
AffiliationIARC, Lyon, France.
MetadataShow full item record
AbstractTo investigate the clinical value of somatic TP53 mutations in breast cancer, we assembled clinical and molecular data on 1,794 women with primary breast cancer with long-term follow-up and whose tumor has been screened for mutation in exons 5 to 8 of TP53 by gene sequencing. TP53 mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype (high grade, large size, node positive cases, and low hormone receptor content) and in women <60 years old. TP53 mutations within exons 5 to 8 conferred an elevated risk of breast cancer-specific death of 2.27 (relative risk >10 years; P < 0.0001) compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status, and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179 and R248W) seem to be associated with an even worse prognosis. These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice.
CitationThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. 2006, 12 (4):1157-67 Clin. Cancer Res.
JournalClinical Cancer Research
- TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
- Authors: de Anta JM, Jassem E, Rosell R, Martínez-Roca M, Jassem J, Martínez-López E, Monzó M, Sánchez-Hernández JJ, Moreno I, Sánchez-Céspedes M
- Issue date: 1997 Dec 11
- A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
- Authors: Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J
- Issue date: 2008
- Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
- Authors: Kuo SJ, Chen M, Ma GC, Chen ST, Chang SP, Lin WY, Chen YC, Lee TH, Lin TT, Liu CS
- Issue date: 2010 Sep
- p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
- Authors: Shao ZM, Wu J, Shen ZZ, Nguyen M
- Issue date: 2001 Aug
- Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
- Authors: Ständer M, Peraud A, Leroch B, Kreth FW
- Issue date: 2004 Sep 1